Angiogenic gene therapy does not cause retinal pathology

Abstract

Background: The potential negative influence of angiogenic gene therapy on the development or progression of retinal pathologies such as diabetic retinopathy (DR) or age-related macular degeneration (AMD) has led to the systematic exclusion of affected patients from trials. We investigated the role of nonviral fibroblast factor 1 (NV1FGF) in two phase II, multinational, double-blind, randomized, placebo-controlled, gene therapy trials (TALISMAN 201 and 211). Methods: One hundred and fifty-two subjects with critical limb ischemia or claudication were randomized to receive eight intramuscular injections of 2.5ml of NV1FGF at 0.2mg/ml or 0.4mg/dl or placebo. One hundred and fifty-two patients received a plasmid dose of NV1FGF of up to 32mg or placebo. All patients underwent a systematic ophthalmologic examination at baseline and at 3, 6 or 12months following gene therapy. Twenty-six of these patients (Münster subgroup) received a retinal fluorescence angiography at baseline and at final examination. Results: Among those 26 patients, four of nine patients with diabetes suffered from nonproliferative DR. Three patients showed non-exsudative AMD. No change of retinal morphology or function was observed in Münster subgroup of both TALISMAN trials independent of the intramuscular NV1FGF dosage applied. Conclusions: Angiogenic gene therapy using NV1FGF is safe even in diabetics.